Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Description Intervention
Aman et al., 2005
McDougle et al.,
2005^
Arnold et al.,
2003†
RUPP, 2002‡
Williams et al,
2006º
Anderson et al.,
2007ª
Aman et al., 2008§
Martin et al.,
2004¥
(continued)
Inclusion/ Exclusion
Criteria/ Population
C-132
Baseline
Measures Outcomes
phase, month 4,
%:
Excessive
appetite:
G1: 49.1
Enuresis:
G1: 35.1
Tired during day:
G1: 21.1
Dry mouth:
G1: 15.8
Coughing:
G1: 12.3
Anxiety:
G1: 14.0
Rhinitis:
G1: 15.8
Excess saliva: G1:
15.8
Nausea/vomiting:
G1: 10.5
Difficulty falling
asleep:
G1: 10.5
Gynecomastia:
G1: 7.0
Difficulty waking:
G1: 5.3
Diarrhea:
G1: 3.5
Constipation:
G1: 3.5
Skin rash:
G1: 8.8
Muscles “stuck”:
G1: 3.5
Withdrew due to
AEs, extension
phase:
G1: 1
(constipation)
Modifiers:
No clinical
complaints or
physical findings
associated with
changes in
prolactin; no
significant effects
of DRD2 polymorphisms
on
changes in serum
prolactin from
baseline to end of
RCTª
Comments: * 30 from the RCT risperidone group, 30 from the placebo non-responders, and 3 who did not meet open label
response criteria but were still included in phase.